Randomized trial of Time-Limited interruptions of protease Inhibitor-Based antiretroviral therapy (art) vs. continuous therapy for HIV-1 infection

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Firnhaber, Cynthia ^a   Azzoni, Livio ^b   Foulkes, Andrea S ^c   Gross, Robert ^d   Yin, Xiangfan ^b   van Amsterdam, Desiree ^a   Schulze, Doreen ^a   Glencross, Deborah K ^e   Stevens, Wendy ^e   Hunt, Gillian ^f   Morris, Lynn ^f   Fox, Lawrence ^g   Sanne, Ian ^a   Montaner, Luis J ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b WISTAR INSTITUTE   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^f NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LOPINAVIR; RITONAVIR;

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTINUOUS THERAPY; CONTROLLED STUDY; DRUG INTERMITTENT THERAPY; DRUG SUBSTITUTION; DRUG THERAPY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; SOUTH AFRICA; TREATMENT DURATION; VIROTHERAPY; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; LAMIVUDINE; LOPINAVIR; PROTEASE INHIBITORS; RITONAVIR; STAVUDINE; ZIDOVUDINE;

EID: 79959580478     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021450     Document Type: Article

References (33)

1. El-Sadr WM, Hoos D, (2008) The President's Emergency Plan for AIDS Relief-is the emergency over? N Engl J Med 359: 553-555.
2. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, et al. (2006) Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 296: 679-690.
3. Tuller D, (2010) Trying to Follow the Trail of Missing AIDS Patients. The New York Times. US ed New York The New York Times Company.
4. Weiser SD, Tuller DM, Frongillo EA, Senkungu J, Mukiibi N, et al. Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda. PLoS One 5: e10340.
5. O'Brien DP, Venis S, Greig J, Shanks L, Ellman T, et al. Provision of antiretroviral treatment in conflict settings: the experience of Medecins Sans Frontieres. Confl Health 4: 12.
6. Kranzer K, Lewis JJ, Ford N, Zeinecker J, Orrell C, et al. (2010) Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr 55: e17-23.
7. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355: 2283-2296.
8. Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, et al. (2008) Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis 197: 1145-1155.
9. Touloumi G, Pantazis N, Antoniou A, Stirnadel HA, Walker SA, et al. (2006) Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. J Acquir Immune Defic Syndr 42: 554-561.
10. Danel C, Moh R, Chaix ML, Gabillard D, Gnokoro J, et al. (2009) Two-months-off, four-months-on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: a randomized trial involving West African adults. J Infect Dis 199: 66-76.
11. Ananworanich J, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, et al. (2006) CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 368: 459-465.
12. DART (2008) Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts <200 cells/microl. AIDS 22: 237-247.
13. Palmisano L, Giuliano M, Bucciardini R, Fragola V, Andreotti M, et al. (2007) Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: the Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study. J Acquir Immune Defic Syndr 46: 39-47.
14. Marchou B, Tangre P, Charreau I, Izopet J, Girard PM, et al. (2007) Intermittent antiretroviral therapy in patients with controlled HIV infection. AIDS 21: 457-466.
15. Jacobson JM, Pat Bucy R, Spritzler J, Saag MS, Eron JJ Jr, et al. (2006) Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis 194: 623-632.
16. Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, et al. (2004) Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med 1: e64.
17. Paton NI, (2008) Treatment interruption strategies: how great are the risks? Curr Opin Infect Dis 21: 25-30.
18. Ananworanich J, Hirschel B, (2007) Intermittent therapy for the treatment of chronic HIV infection. AIDS 21: 123-134.
19. Division of AIDS N (2004) Table for Grading, Severity of Adverse Events II.
20. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, et al. (2006) Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 20: 995-1002.
21. Dybul M, Nies-Kraske E, Daucher M, Hertogs K, Hallahan CW, et al. (2003) Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis 188: 388-396.
22. Leon A, Martinez E, Milinkovic A, Mora B, Mallolas J, et al. (2009) Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption. J Antimicrob Chemother 63: 184-188.
23. Kikaire B, Khoo S, Walker AS, Ssali F, Munderi P, et al. (2007) Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. AIDS 21: 733-737.
24. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, et al. (2003) Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 31: 298-303.
25. Gross R, Bilker WB, Friedman HM, Strom BL, (2001) Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 15: 2109-2117.
26. Gross R, Bilker WB, Wang H, Chapman J, (2008) How long is the window of opportunity between adherence failure and virologic failure on efavirenz-based HAART? HIV Clin Trials 9: 202-206.
27. Posse M, Baltussen R, (2009) Barriers to access to antiretroviral treatment in Mozambique, as perceived by patients and health workers in urban and rural settings. AIDS Patient Care STDS 23: 867-875.
28. Stephen H, Roberts B, (2009) A case study of the provision of antiretroviral therapy for refugees in Tanzania. Med Confl Surviv 25: 134-147.
29. Marcellin F, Boyer S, Protopopescu C, Dia A, Ongolo-Zogo P, et al. (2008) Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaounde, Cameroon (EVAL survey, ANRS 12-116). Trop Med Int Health 13: 1470-1478.
30. Cantrell RA, Sinkala M, Megazinni K, Lawson-Marriott S, Washington S, et al. (2008) A pilot study of food supplementation to improve adherence to antiretroviral therapy among food-insecure adults in Lusaka, Zambia. J Acquir Immune Defic Syndr 49: 190-195.
31. Beyene KA, Gedif T, Gebre-Mariam T, Engidawork E, (2009) Highly active antiretroviral therapy adherence and its determinants in selected hospitals from south and central Ethiopia. Pharmacoepidemiol Drug Saf 18: 1007-1015.
32. Diabate S, Alary M, Koffi CK, (2007) Determinants of adherence to highly active antiretroviral therapy among HIV-1-infected patients in Cote d'Ivoire. AIDS 21: 1799-1803.
33. Kiguba R, Byakika-Tusiime J, Karamagi C, Ssali F, Mugyenyi P, et al. (2007) Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors. J Acquir Immune Defic Syndr 45: 218-223.